Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Archives of Pathology & Laboratory Medicine|June 4, 2023
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic ApproachSusana Hernandez, Esther Conde, Aida Molero, et al.
Cancer Immunology Research|June 14, 2019
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast CancerAura Muntasell, Sònia Servitja, Mariona Cabo, et al.
Science Advances|May 20, 2022
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancerAnna Adam-Artigues, Enrique J Arenas, Alex Martínez-Sabadell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast CancerMohammadA Sabbaghi, Gabriel Gil-Gómez, Cristina Guardia, et al.
Frontiers in Artificial Intelligence|May 6, 2026
Brief report: Artificial intelligence meets small cell lung cancer-integrating clinicopathological and wholeslide image data for prognostic prediction in SCLCPedro Rocha, Joan Gibert, Silvía Menendez, et al.
European Journal of Cancer (Oxford, England : 1990)|September 7, 2019
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversionAna Lluch, Ana M González-Angulo, David Casadevall, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 5, 2012
mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish studyLaia Bernet, Marcos Martinez Benaclocha, Carles Castera, et al.
Oncotarget|January 7, 2017
2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implicationsNieves González, Isabel Prieto, Laura Del Puerto-Nevado, et al.
Current Medical Research and Opinion|April 9, 2015
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancerMiguel Martín, Milagros González-Rivera, Serafín Morales, et al.
Cancers|November 13, 2021
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) StudyLuis de la Cruz-Merino, María Gion, Josefina Cruz-Jurado, et al.
Pageof 23